PT UBC Medical Indonesia Tbk (LABS) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of PT UBC Medical Indonesia Tbk stock IDR 75, price IDR 121, that is 37.8% below the price, quality 62 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
28‑month range 109.00 IDR – 216.00 IDR · fair‑value band 53.71 IDR – 94.03 IDR · the 121.00 IDR price screens above the 75.23 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow PT UBC Medical Indonesia Tbk in your weekly email
Every Wednesday you see whether PT UBC Medical Indonesia Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT UBC Medical Indonesia Tbk engages in the marketing and distribution of medical devices in Indonesia. The company operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment.
Show moreShow less
It offers TB management, newborn screening, HPV DNA test, real time PCR, infectious disease, extraction kit, all-in-one GP workstation, hisky, and AIRDOC products.
The company also wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and chemical products and traditional medicine. The company was founded in 2014 and is based in Jakarta Timur, Jakarta.
PT UBC Medical Indonesia Tbk operates as a subsidiary of PT Optel Investama Mulia.
Stock analysis
PT UBC Medical Indonesia Tbk (LABS) currently trades at 121.00 IDR, while our model-based Fair Value estimate is 75.23 IDR, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 115.48 IDR per share, and 5 of the 23 models we run sit above the 121.00 IDR price.
Bear case: the Asset-Based group reads lowest at 27.02 IDR, and 18 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: 53.71 IDR (bear) to 94.03 IDR (bull), the price of 121.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
PT UBC Medical Indonesia Tbk reported revenue of 199B IDR in FY2025 versus 130B IDR in FY2021, a compound +11.3%/yr. Reported net income was 13.5B IDR in FY2025, compounding +157.3%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 478B IDR (≈ $26.5M) Micro · P/S ratio 2.39 · Net margin 5.1% · Return on equity 7.1% · Return on assets (EBIT) 4.7% (5-year average) · Operating margin 11.6% · Revenue (TTM) 208B IDR · Revenue growth (YoY) +3.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −38%, LABS screens richer than that median.
Fair Value models
Bear53.71 IDRFair Value 75.23 IDRBull94.03 IDR
Price 121.00 IDR · Downside -37.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+35.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +96.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+96.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 10%
⚠ Approximate: the rate leans on 2025, which sits 219% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +30.1% a year for the price.
Compare PT UBC Medical Indonesia Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−38.3% · Below median
Profitability
Return on equity (12 months)7.1% · Above median
Return on assets5.9% · Above median
Net margin (12 months)5.1% · Below median
Operating margin (12 months)11.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)3.7% · Below median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PT UBC Medical Indonesia Tbk Fair Value". https://www.fairvalue-calculator.com/stock/LABS
Frequently asked questions
Is PT UBC Medical Indonesia Tbk (LABS) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 75.23 IDR versus a price of 121.00 IDR, about 38% lower (overvalued).
What is the fair value of LABS?
Our model-based fair value for PT UBC Medical Indonesia Tbk is 75.23 IDR (as of Nov 3, 2026), built from audited fundamentals. The current price: 121.00 IDR.
What is the quality score of LABS?
PT UBC Medical Indonesia Tbk has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PT UBC Medical Indonesia Tbk (LABS)?
Our model-based price target is the fair value of 75.23 IDR (as of Nov 3, 2026) from 23 valuation models. Cautious scenario 53.71 IDR, optimistic scenario 94.03 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the PT UBC Medical Indonesia Tbk stock forecast for 2026?
Our models put fair value at 75.23 IDR, about 38% lower versus a price of 121.00 IDR (overvalued). Cautious scenario 53.71 IDR, optimistic scenario 94.03 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of PT UBC Medical Indonesia Tbk (LABS)?
PT UBC Medical Indonesia Tbk reported trailing-twelve-month revenue of about 208B IDR (latest available figure, as of Nov 3, 2026).
What growth is priced into PT UBC Medical Indonesia Tbk (LABS)?
For today's price to be fair in a discounted-cash-flow model, PT UBC Medical Indonesia Tbk would have to grow free cash flow by +33.6 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +11.3 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of LABS use?
Our models discount PT UBC Medical Indonesia Tbk at 12.0 %: a base by market capitalisation (nano), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PT UBC Medical Indonesia Tbk that is +33.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has PT UBC Medical Indonesia Tbk (LABS) delivered so far?
Over the past 4 years revenue at PT UBC Medical Indonesia Tbk grew +11.3 % a year. The price currently implies free-cash-flow growth of +33.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PT UBC Medical Indonesia Tbk (LABS) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into PT UBC Medical Indonesia Tbk (+33.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PT UBC Medical Indonesia Tbk (LABS)?
The free-cash-flow yield on the price is 1.82 %: that much free cash flow PT UBC Medical Indonesia Tbk produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PT UBC Medical Indonesia Tbk (LABS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PT UBC Medical Indonesia Tbk it is 75.23 IDR per share (as of Nov 3, 2026), against a price of 121.00 IDR. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is PT UBC Medical Indonesia Tbk stock overvalued or undervalued in 2026?
As of Nov 3, 2026, LABS trades above its calculated fair value: price 121.00 IDR, fair value 75.23 IDR, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LABS?
No. The price is what the market pays today (121.00 IDR); the fair value is what the company's own numbers justify (75.23 IDR). For PT UBC Medical Indonesia Tbk the two are 45.77 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is PT UBC Medical Indonesia Tbk worth?
The market values PT UBC Medical Indonesia Tbk at about 478B IDR (market capitalisation, as of Nov 3, 2026). Per share that is 121.00 IDR; our models calculate a fair value of 75.23 IDR per share.
What do the bullish and bearish scenarios say about LABS?
Our models span a range for PT UBC Medical Indonesia Tbk: cautious scenario 53.71 IDR, base 75.23 IDR, optimistic 94.03 IDR per share (as of Nov 3, 2026, price 121.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PT UBC Medical Indonesia Tbk (LABS)?
Balance-sheet figures for PT UBC Medical Indonesia Tbk (as of Nov 3, 2026): return on equity 7.1%, debt of 0.01 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is LABS from its 52-week high?
PT UBC Medical Indonesia Tbk trades at 121.00 IDR, about 44% below its 52-week high of 216.00 IDR and at the low of 121.00 IDR (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 75.23 IDR is for.
Which stocks are comparable to PT UBC Medical Indonesia Tbk?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PT UBC Medical Indonesia Tbk stock attractive at the current price?
The data as of Nov 3, 2026: price 121.00 IDR, calculated fair value 75.23 IDR (−38%), Quality Score 62/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LABS calculated?
We run PT UBC Medical Indonesia Tbk through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 75.23 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. PT UBC Medical Indonesia Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PT UBC Medical Indonesia Tbk (LABS)?
The closing price on Nov 9, 2026 was 121.00 IDR. Our model-based fair value is 75.23 IDR, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PT UBC Medical Indonesia Tbk right now?
The price sits above even our optimistic bull case (94.03 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of PT UBC Medical Indonesia Tbk
How large is the market capitalisation of PT UBC Medical Indonesia Tbk (LABS)?
The market capitalisation of PT UBC Medical Indonesia Tbk is 478B IDR (≈ $26.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PT UBC Medical Indonesia Tbk (LABS)?
The price-to-sales ratio of PT UBC Medical Indonesia Tbk is 2.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PT UBC Medical Indonesia Tbk (LABS)?
The net margin of PT UBC Medical Indonesia Tbk is 5.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PT UBC Medical Indonesia Tbk (LABS)?
The return on equity (ROE) of PT UBC Medical Indonesia Tbk is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PT UBC Medical Indonesia Tbk (LABS)?
On an EBIT basis the return on assets of PT UBC Medical Indonesia Tbk is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PT UBC Medical Indonesia Tbk (LABS)?
The operating margin of PT UBC Medical Indonesia Tbk is 11.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PT UBC Medical Indonesia Tbk (LABS)?
Revenue at PT UBC Medical Indonesia Tbk is growing +3.7% versus a year earlier (3y avg +28.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PT UBC Medical Indonesia Tbk (LABS)?
Earnings per share at PT UBC Medical Indonesia Tbk are growing −26.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does PT UBC Medical Indonesia Tbk (LABS) hold?
PT UBC Medical Indonesia Tbk holds more cash than debt, 13.7B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PT UBC Medical Indonesia Tbk in the live analysis
One click puts PT UBC Medical Indonesia Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026